TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Inro Biomedtek AB
Closing information (x1000 EUR)
| Closing information | 2025/12 | 2024/12 | 2023/12 |
| Turnover |
38
|
43 | |
| Financial expenses |
0
|
111 | |
| Earnings before taxes |
26
|
-51 | |
| EBITDA |
30
|
35 | |
| Total assets |
56
|
1,221 | |
| Current assets |
48
|
1,208 | |
| Current liabilities |
5
|
85 | |
| Equity capital |
51
|
1,136 | |
| - share capital |
9
|
9 | |
| Employees (average) |
1
|
1
|
1 |
Financial ratios
| Fiscal year | 2025/12 | 2024/12 | 2023/12 |
| Solvency |
91.1%
|
93.0% | |
| Turnover per employee |
38
|
43 | |
| Profit as a percentage of turnover |
68.4%
|
-118.6% | |
| Return on assets (ROA) |
46.4%
|
4.9% | |
| Current ratio |
960.0%
|
1421.2% | |
| Return on equity (ROE) |
51.0%
|
-4.5% | |
| Change turnover |
-4
|
8 | |
| Change turnover % |
-8%
|
-10%
|
21% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
0%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2025/12 | 2024/12 | 2023/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.